AIRLINK 74.85 Increased By ▲ 0.56 (0.75%)
BOP 4.98 Increased By ▲ 0.03 (0.61%)
CNERGY 4.49 Increased By ▲ 0.12 (2.75%)
DFML 40.00 Increased By ▲ 1.20 (3.09%)
DGKC 86.35 Increased By ▲ 1.53 (1.8%)
FCCL 21.36 Increased By ▲ 0.15 (0.71%)
FFBL 33.85 Decreased By ▼ -0.27 (-0.79%)
FFL 9.72 Increased By ▲ 0.02 (0.21%)
GGL 10.45 Increased By ▲ 0.03 (0.29%)
HBL 112.74 Decreased By ▼ -0.26 (-0.23%)
HUBC 137.44 Increased By ▲ 1.24 (0.91%)
HUMNL 11.42 Decreased By ▼ -0.48 (-4.03%)
KEL 5.28 Increased By ▲ 0.57 (12.1%)
KOSM 4.63 Increased By ▲ 0.19 (4.28%)
MLCF 37.80 Increased By ▲ 0.15 (0.4%)
OGDC 139.50 Increased By ▲ 3.30 (2.42%)
PAEL 25.61 Increased By ▲ 0.51 (2.03%)
PIAA 20.68 Increased By ▲ 1.44 (7.48%)
PIBTL 6.80 Increased By ▲ 0.09 (1.34%)
PPL 122.20 Increased By ▲ 0.10 (0.08%)
PRL 26.58 Decreased By ▼ -0.07 (-0.26%)
PTC 14.05 Increased By ▲ 0.12 (0.86%)
SEARL 58.98 Increased By ▲ 1.76 (3.08%)
SNGP 68.95 Increased By ▲ 1.35 (2%)
SSGC 10.30 Increased By ▲ 0.05 (0.49%)
TELE 8.38 Decreased By ▼ -0.02 (-0.24%)
TPLP 11.06 Decreased By ▼ -0.07 (-0.63%)
TRG 64.19 Increased By ▲ 1.38 (2.2%)
UNITY 26.55 Increased By ▲ 0.05 (0.19%)
WTL 1.45 Increased By ▲ 0.10 (7.41%)
BR100 7,841 Increased By 30.9 (0.4%)
BR30 25,465 Increased By 315.4 (1.25%)
KSE100 75,114 Increased By 157.8 (0.21%)
KSE30 24,114 Increased By 30.8 (0.13%)
Business & Finance

Russia's Sputnik V developers to sue Brazilian regulator for 'false information' about their vaccine

  • The board of Brazilian health regulator on Monday rejected importing Sputnik V after technical staff warned of flaws in its development along with incomplete data regarding the vaccine's safety and efficacy.
  • A crucial issue for the Brazilian regulator was the risk of other viruses used to make the vaccine reproducing in patients, which an Anvisa expert had called a "serious" defect.
Published April 29, 2021

MOSCOW: Russian developers of the Sputnik V vaccine against COVID-19 said on Thursday that they were suing Brazilian regulator Anvisa for defamation, accusing it of having knowingly spread false information without testing their product.

The board of Brazilian health regulator on Monday rejected importing Sputnik V after technical staff warned of flaws in its development along with incomplete data regarding the vaccine's safety and efficacy.

A crucial issue for the Brazilian regulator was the risk of other viruses used to make the vaccine reproducing in patients, which an Anvisa expert had called a "serious" defect.

Sputnik V's official Twitter account on Thursday cited a Brazilian media story citing the same expert as saying that no tests had been carried out to test the Brazilian theory.

"Following the admission of Brazilian regulator Anvisa that it did not test Sputnik V vaccine, Sputnik V is undertaking a legal defamation proceeding in Brazil against Anvisa for knowingly spreading false and inaccurate information," it said.

"Anvisa made incorrect and misleading statements without having tested the actual Sputnik V vaccine."

Comments

Comments are closed.